Kurs
+0,96%
Likviditet
5 356 MSEK
Kalender
Est. tid* | ||
2025-04-29 | - | Kvartalsrapport 2025-Q1 |
2025-04-11 | - | Årsstämma |
2025-02-20 | - | X-dag halvårsutdelning AZN 167.999995 |
2025-02-06 | - | Bokslutskommuniké 2024 |
2024-11-12 | - | Kvartalsrapport 2024-Q3 |
2024-08-08 | - | X-dag halvårsutdelning AZN 77.600002 |
2024-07-25 | - | Kvartalsrapport 2024-Q2 |
2024-04-25 | - | Kvartalsrapport 2024-Q1 |
2024-04-11 | - | Årsstämma |
2024-02-22 | - | X-dag halvårsutdelning AZN 155.999994 |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-08-10 | - | X-dag halvårsutdelning AZN 71.799999 |
2023-07-28 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | Årsstämma |
2023-04-27 | - | Kvartalsrapport 2023-Q1 |
2023-02-23 | - | X-dag halvårsutdelning AZN 162.800002 |
2023-02-09 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-11 | - | X-dag halvårsutdelning AZN 76.4 |
2022-07-29 | - | Kvartalsrapport 2022-Q2 |
2022-04-29 | - | Årsstämma |
2022-04-29 | - | Kvartalsrapport 2022-Q1 |
2022-02-24 | - | X-dag halvårsutdelning AZN 145.299995 |
2022-02-10 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-12 | - | X-dag halvårsutdelning AZN 64.8 |
2021-07-29 | - | Kvartalsrapport 2021-Q2 |
2021-05-11 | - | Årsstämma |
2021-04-30 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | X-dag halvårsutdelning AZN 137.399995 |
2021-02-11 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-13 | - | X-dag halvårsutdelning AZN 69.599998 |
2020-07-30 | - | Kvartalsrapport 2020-Q2 |
2020-04-29 | - | Årsstämma |
2020-04-29 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | X-dag halvårsutdelning AZN 146.399999 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-08-08 | - | X-dag halvårsutdelning AZN 71.899998 |
2019-07-25 | - | Kvartalsrapport 2019-Q2 |
2019-04-26 | - | Årsstämma |
2019-04-26 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | X-dag halvårsutdelning AZN 146.800005 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-08 | - | Kvartalsrapport 2018-Q3 |
2018-08-09 | - | X-dag halvårsutdelning AZN 68.400002 |
2018-07-26 | - | Kvartalsrapport 2018-Q2 |
2018-05-18 | - | Årsstämma |
2018-05-18 | - | Kvartalsrapport 2018-Q1 |
2018-02-15 | - | X-dag halvårsutdelning AZN 133.599997 |
2018-02-02 | - | Bokslutskommuniké 2017 |
2017-11-09 | - | Kvartalsrapport 2017-Q3 |
2017-08-10 | - | X-dag halvårsutdelning AZN 68.900001 |
2017-07-27 | - | Kvartalsrapport 2017-Q2 |
2017-04-27 | - | Årsstämma |
2017-04-27 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | X-dag halvårsutdelning AZN 150.199997 |
2017-02-02 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-11 | - | X-dag halvårsutdelning AZN 68.699998 |
2016-07-28 | - | Kvartalsrapport 2016-Q2 |
2016-04-29 | - | Årsstämma |
2016-04-29 | - | Kvartalsrapport 2016-Q1 |
2016-02-18 | - | X-dag halvårsutdelning AZN 145.555556 |
2016-02-04 | - | Bokslutskommuniké 2015 |
2015-11-05 | - | Kvartalsrapport 2015-Q3 |
2015-08-13 | - | X-dag halvårsutdelning AZN 63.88889 |
2015-07-30 | - | Kvartalsrapport 2015-Q2 |
2015-04-24 | - | Årsstämma |
2015-04-24 | - | Kvartalsrapport 2015-Q1 |
2015-02-19 | - | X-dag halvårsutdelning AZN 138.888896 |
2015-02-05 | - | Bokslutskommuniké 2014 |
2014-11-06 | - | Kvartalsrapport 2014-Q3 |
2014-08-13 | - | X-dag halvårsutdelning AZN 59 |
2014-07-31 | - | Kvartalsrapport 2014-Q2 |
2014-04-24 | - | Årsstämma |
2014-04-24 | - | Kvartalsrapport 2014-Q1 |
2014-02-19 | - | X-dag halvårsutdelning AZN 129.777777 |
2014-02-06 | - | Bokslutskommuniké 2013 |
2013-10-31 | - | Kvartalsrapport 2013-Q3 |
2013-08-14 | - | X-dag halvårsutdelning AZN 65.777779 |
2013-08-01 | - | Analytiker möte 2013 |
2013-08-01 | - | Kvartalsrapport 2013-Q2 |
2013-04-25 | - | Årsstämma |
2013-04-25 | - | Kvartalsrapport 2013-Q1 |
2013-02-13 | - | X-dag halvårsutdelning AZN 133.888888 |
2013-01-31 | - | Bokslutskommuniké 2012 |
2012-10-25 | - | Analytiker möte 2012 |
2012-10-25 | - | Kvartalsrapport 2012-Q3 |
2012-08-08 | - | X-dag halvårsutdelning AZN 64.555556 |
2012-07-26 | - | Kvartalsrapport 2012-Q2 |
2012-04-26 | - | Årsstämma |
2012-04-26 | - | Kvartalsrapport 2012-Q1 |
2012-02-15 | - | X-dag halvårsutdelning AZN 137.333333 |
2012-02-02 | - | Bokslutskommuniké 2011 |
2011-10-27 | - | Kvartalsrapport 2011-Q3 |
2011-08-03 | - | X-dag halvårsutdelning AZN 57.666665 |
2011-07-28 | - | Kvartalsrapport 2011-Q2 |
2011-04-28 | - | Årsstämma |
2011-04-28 | - | Kvartalsrapport 2011-Q1 |
2011-02-02 | - | X-dag halvårsutdelning AZN 129.666662 |
2011-01-27 | - | Bokslutskommuniké 2010 |
2010-10-28 | - | Kvartalsrapport 2010-Q3 |
2010-08-04 | - | X-dag halvårsutdelning AZN 49.888888 |
2010-07-29 | - | Kvartalsrapport 2010-Q2 |
2010-04-29 | - | Kvartalsrapport 2010-Q1 |
2010-02-03 | - | X-dag halvårsutdelning AZN 117.111111 |
2010-01-28 | - | Bokslutskommuniké 2009 |
2009-10-29 | - | Kvartalsrapport 2009-Q3 |
2009-08-05 | - | X-dag halvårsutdelning AZN 40 |
2009-07-30 | - | Kvartalsrapport 2009-Q2 |
2009-04-30 | - | Årsstämma |
2009-04-30 | - | Kvartalsrapport 2009-Q1 |
2009-02-04 | - | X-dag halvårsutdelning AZN 116.444444 |
2008-08-06 | - | X-dag halvårsutdelning AZN 30.888888 |
2008-02-06 | - | X-dag halvårsutdelning AZN 75.2222222 |
2007-08-08 | - | X-dag halvårsutdelning AZN 28.111111 |
2007-02-07 | - | X-dag halvårsutdelning AZN 70 |
2006-08-09 | - | X-dag halvårsutdelning AZN 32.562658 |
Beskrivning
Land | Storbritannien |
---|---|
Lista | FTSE 100 |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
National Resilience, Inc. to expand site and support future growth of its medicines manufacturing capabilities.
AstraZeneca today announces the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines.
Andrew Wirths, Senior Vice President, Americas Supply Region, AstraZeneca, said: "As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio. The transfer of our West Chester site to Resilience will enable the continued supply of AstraZeneca medicines to patients, as well as the continued employment for more than 500 people working at the West Chester site. I'm encouraged by Resilience's plans to transform the site into their drug product centre of excellence."
"The West Chester site will play an important role in the delivery of our mission to broaden access to complex medicines, protect biopharmaceutical supply chains, and strengthen domestic preparedness," said Rahul Singhvi, Sc.D, Chief Executive Officer of Resilience. "I'm confident that West Chester's premier capabilities, including the talented employees who are joining Resilience, will help us expand our business in new directions."
AstraZeneca expects to complete the sale in the first quarter of 2023, with a phased transition of services.
Notes
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).
About Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients' lives by continuously advancing the science of biopharmaceutical manufacturing and development. For more information, visit www.Resilience.com (https://protect-de.mimecast.com/s/NxevCpZ4qntxKEYyRuD1exd?domain=cts.businesswire.com) and follow us on social media: @IncResilience (https://protect-de.mimecast.com/s/lUHtCqQgrou7l6qRMUQC85a?domain=cts.businesswire.com)on Twitter and Resilience (https://protect-de.mimecast.com/s/_ma3Cr2jvpCDo3g6BcyjAuH?domain=cts.businesswire.com) on LinkedIn.